Cargando…
A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients
Objective: A severe complication in the replacement therapy of hemophilia A (HA) patients is the development of alloantibodies (inhibitors) against factor VIII, which neutralizes the substituted factor. The primary genetic risk factors influencing the development of inhibitors are F8 gene mutations....
Autores principales: | Fidancı, İnanç Değer, Zülfikar, Bülent, Kavaklı, Kaan, Ar, M. Cem, Kılınç, Yurdanur, Başlar, Zafer, Çağlayan, Server Hande |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996645/ https://www.ncbi.nlm.nih.gov/pubmed/24764725 http://dx.doi.org/10.4274/Tjh.2012.0197 |
Ejemplares similares
-
Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019) -
Osteoporosis in Patients With Hemophilia: Single-Center Results From a Middle-Income Country
por: Sahin, Serdar, et al.
Publicado: (2019) -
Participation in Physical and Sportive Activities among Adult Turkish People with Hemophilia: A Single-Center Experience
por: Lehmeier, Arni, et al.
Publicado: (2018) -
Prospective Evaluation of Non-Compliant Severe Hemophilia Patients
por: Uğur, Mehmet Can, et al.
Publicado: (2019) -
Persons With Hemophilia of Generation Y and Their Relatives Attitudes and Expectations From Treatment
por: Zulfikar, Bulent, et al.
Publicado: (2021)